https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=10652
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=10652
No pharmaceutical opinion available for this interaction.
–
–
Tivicay, Triumeq ou Dovato : No dosage adjustment is necessary.
Juluca : Take 25 mg of rilpivirine with Juluca tablet during co-administration.
–
–
–
–
–
–
| Reference number |
|---|
| # patients |
| HIV |
| Dose |
| Frequency |
| Duration (days) |
| AUC |
| Cmax |
| Cmin |
| 2723 |
|---|
| 9 |
| - |
| 50 mg |
| QD |
| 14 |
| - 5% |
| + 15% |
| - 30% * |
| 2723 |
|---|
| 9 |
| - |
| 300 mg |
| QD |
| 14 |
Ref #2723 : * This decrease is unlikely to be clinically significant effect in integrase inhibitor-naive patients.
Ref #3662: To characterize the pharmacokinetics of dolutegravir when co-administered with rifabutin, this analysis includes data from two existing studies in a model describing the population pharmacokinetics of dolutegravir. Simulations showed that rifabutin decreased the volume of distribution of dolutegravir by 33.1%, but did not affect the area under the concentration-time curve. They also demonstrated that when 50 mg of dolutegravir is co-administered with rifabutin QD, the probability of achieving trough concentrations above the IC90 of 0.064 mg/L was greater than 99%.